業績

2023年　発表論文一覧　　2024年4月現在

研究No	執筆者/論文タイトル/掲載誌
WJOG8916G	Naoki Izawa, et al. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild‑Type mCRC Refractory to Prior Anti‑EGFR Antibodies: WJOG8916G Trial. Targeted Oncology, https://doi.org/10.1007/s11523-023-00963-9.
WJOGG11619L	Motko Tachihara, et al. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer. The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023;9(11):1505-1513. doi:10.1001/jamaoncol.2023.3309.
LOGIK1603/ WJOG9116L	Kazushige Wakuda, et al. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L). JTO Clinical and Research Reports Vol. 4 No. 12: 100587
WJOG10818L バイオマーカー	Kimio Yonesaka, et al. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial Clin Lung Cancer. Volume 24, Issue 6, September 2023, Pages 519-527.e4
WJOG12319LTR	Junko Tanizaki, et al. Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy. JTO Clinical and Research Reports Vol. 4 No. 12: 100590
WJOG13119L	Takeshi Masuda, et al. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. Sci Rep. 2023 Nov 13;13(1):19729. doi: 10.1038/s41598-023-45337-3.
WJOG14720L	Kazushige Wakuda, et al. Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L) BMC Cancer. 2023 Sep 25;23(1):902.
WJOG11518L	Koji Haratani, et al. Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE) J Thorac Oncol. 2023 Oct;18(10):1334-1350.
WJOG11518L	Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.Haratani K,Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y, Hata A, Tsuruno K,Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y,Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H.Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662-2. Online ahead of print.
WJOG11318B	Hiroko Masuda, et al. Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B) The Breast. 2023 Oct:71:22-28.
WJOG14520G	Yosuke Kito, et al. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)Oncologist. 2023 Nov 10:oyad296
WJOG11218L	Yoshimasa Shiraishi,et al. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2023 Dec 21:e235258. doi: 10.1001/jamaoncol.2023.5258.
WJOG15421L	Sakamoto T, et al. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer JAMA Netw Open. 2023 Dec 1;6(12):e2347700
WJOG15822G	(Study Protocol)Naoki Takahashi. et al. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM)versus trifluridine/tipiracil for previously treated patients with advanced gastricor esophagogastric junction adenocarcinoma(RETRIEVE study, WJOG15822G) BMC Cancer (2023) 23:726
WJOG11418B	Jun Masuda, et al.Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126.
WJOG14320B	Hitomi Sakai et al.Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B). BMJ Open. 2023 Apr 3;13(4):e070304. doi: 10.1136/bmjopen-2022-070304. PMID: 37012013; PMCID: PMC10083740.
WJOG11919L	Ozawa Y, et al. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L) Ther Adv Med Oncol. 2024 Jan 27:16:17588359231225046.
WJOG16923L	(Study Protocol)Atsushi Kamigaich, et al. A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial). Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00006-8. doi: 10.1016 /j.cllc.2024.01.004
WJOG11018G	Matsumoto, T. M. et al. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G. Targ Oncol (2024). https://doi.org/10.1007/s11523-024-01043-2
WJOG6410LTR	Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M, Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. Mol Oncol. 2024 Feb;18(2):305-316.

2022年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG6410L	Hirohito Tada, et al.Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol . 2022 Jan 20;40(3):231-241.
WJOG10718L	Takashi Seto, et ail.Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). J Immunother Cancer 2022;10:e004025. doi:10.1136/jitc-2021-004025
J-SONIC	Kohei Otsubo, et al.Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal. 15 Dec 2022, 60(6):2200380
WJOG10818L	Hidetoshi Hayashi, et al.Alternating Therapy with Osimertinib and Afatinib forTreatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer Vol. 168p38–45. Published online: April 12, 2022
JCOG0804/ WJOG4507L	Kenji Suzuki, et al. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg 2022；163：289-301
WJOG9917B	Yukinori Ozaki, et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European Journal of Cancer. Volume 171, August 2022, Pages 193-202
WJOG13219G	Keitaro Shimozaki et al. The Efficacy and Safety of FOLFOXIRI or Doublet plus anti-VEGF therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study) . Clinical Colorectal Cancer. In Press Journal Pre-Proof. Published online: August 11, 2022
WJOG7612GTR	Wataru Okamoto et al. Confidential: For Review OnlyA phase II study to explore iomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line　chemotherapy in atients with metastatic colorectal cancer (WJOG7612GTR). ESMO OPEN, Volume 6 Issue 6, P1-10, 2022. (https://doi.org/10.1016/j.esmoop.2022.100592)
WJOG5108LFS	Nobuyuki Katakami et ai. Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). International Journal of Clinical Oncology (2023) 28:79-88.
WJOG8916G	Naoki Izawa et al. A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer refractory to prior anti-EGFR antibodies： the WJOG8916G trial (Targeted Oncology accepted in March 24, 2023)
WJOG9616L	Hiroaki Akamatsu et ai. Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clin Cancer Res; 28(15): 3207-3213, August 1, 2022
JCOG0802/ WJOG4607L	Hisashi Saji et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022 Apr 23;399(10335):1607-1617

2021年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG12519B	Takamichi Yokoe et al.Clinical benefit of treatment after trastuzumab-emtansine for HER2-positive metastatic breast cancer: A real-world multi-centre cohort study in Japan (WJOG12519B). Breast Cancer. 28, pages581–591(2021)
WJOG8815L /LPS/LFS	Kazuko Sakai et al.Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L). Molecular Oncology 15 (2021) 126–137
WJOG8715L	Hiroaki Akamatsu et al.Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021; 7(3):386-394
WJOG0105LFS	Yoshitaka Zenke, et al.Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online March 18, 2021. doi:10.1001/jamaoncol.2021.0113
WJOG13320G	(Study Protocol) Hisato Kawakami et al.An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers 2021, 13(4), 805; https://doi.org/10.3390/cancers13040805
WJOG12119L	(Study Protocol) Akira Hamada et al.Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L) Clinical Lung Cancer Published:April 26, 2021. DOI:https://doi.org/10.1016/j.cllc.2021.04.006.
WJOG11719L	(Study Protocol) Ryota Shibaki et al.A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). Ther Adv Med Oncol　2021, Vol. 13: 1–5.
WJOG12819L	(Study Protocol) Masayuki Takeda, et al.A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical Lung Cancer. VOLUME 22, ISSUE 4, P376-380, JULY 01, 2021
WJOG6911L	Hiroaki Akamatsu, et al.Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. Journal of Thoracic Oncology Vol. 16 No. 10: 1745–1752. 2021
WJOG7312G 副次解析	Hiroyuki Arai, et al.Clinical implications　of using both fluoropyrimidine and paclitaxel in patients with severe　peritoneal metastasis of gastric cancer: A post-hoc study of　JCOG1108/WJOG7312G. Cancer Med. 2021 Nov; 10(21): 7673–7682
WJOG13019L	Shinya Sakata, et al.Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L　Cancer Science. 2022;113:221–228.
WJOG11118L	(Study Protocol) Taichi Miyawaki, et al.Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L) BMC Cancer (2021) 21:1121 https://doi.org/10.1186/s12885-021-08851-z
WJOG8515L	Hidetoshi Hayashi, et al.A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Cancer Res (2022) 28 (5): 893–902.
WJOG9516L	Kentaro Ito, et al.Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. European Journal of Cancer 145 (2021) 183-193.
WJOG11619L	(Study Protocol) Motoko Tachihara, et al.Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research 2021:13 9167–9173.
WJOG9116L	Hiroyuki Yamaguchi, et al.A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). Journal of Thoracic Oncology Vol. 16 No. 12: 2121–2132

2020年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG8815L/LPS	Takayuki Takahama et al. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer 126(9): 1940-1948, 2020
WJOG6811B	Koji Matsumoto et al.A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Medicine. (Web publication in Mar 16, 2020)
WJOG5610L	Takashi Seto et al.Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology 38(8):793-803, 2020
WJOG7112G	Akitaka　Makiyama et al.Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). Journal of Clinical Oncology (Published online: March 24, 2020)
WJOG10217L	Ryoji Kato et al.Propensity Score-Weighted Analysis of Chemotherapy After PD-1 Inhibitors Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Cancer (WJOG10217L). Journal for ImmunoTherapy of Cancer. 2020 Feb;8(1):e000350
WJOG7512L	Tanaka, Kaoru et al.A Randomized Phase III Study of Maintenance Therapy with S-1 Plus Best Supportive Care Versus Best Supportive Care After Induction Therapy with Carboplatin Plus S-1 for Advanced or Relapsed Squamous Cell Carcinoma of the Lung (WJOG7512L). Cancer 126(16): 3648-3656, 2020.
WJOG10617G	Kenro Hirata et al.Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the PSELECT trial (WJOG10617G)—a randomized phase II trial by the West Japan Oncology Group. BMC Cancer (2020) 20:548.
WJOG6510G	Daisuke Sakai et al.Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). European Journal of Cancer. 135: 11-21 (2020) (DOI:https://doi.org/10.1016/j.ejca.2020.04.014)
ASPECCT/ WJOG6510G 統合解析	Hiroya Taniguchi et al.Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. Cancers 2020, 12, 1715; doi:10.3390/cancers12071715
WJOG4407GSS	Ayumu Hosokawa et al.Morphologic response to chemotherapy containing bevacizumab in patinets with colorectal liver metastases. A post hoc analysis of the WJOG4407G phase III study. Medicine. 2020 Sep 4;99(36):e22060. doi:10.1097/MD.0000000000022060.
WJOG6210GSS2	Naoki Izawa.Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). Target Oncology 2020 Oct;15(5):623-633. doi: 10.1007/s11523-020-00750-w.
WJOG4407GSS2	Yuji Miura et al.Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post-hoc analysis (WJOG4407GSS2). Supportive Care Cancer　16 November 2020 (https://doi.org/10.1007/s00520-020-05891-2)
WJOG7813L/ JCOG1210	Isamu Okamoto et al.Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer A Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6(5): e196828
WJOG9516L	Kentaro Ito et al.Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. European Journal of Cancer. 2021; 145: 183-193.
WJOG11218L	(Study Protocol) Yoshimasa Shiraishi et al.Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. VOLUME 21, ISSUE 5, P472-476, SEPTEMBER 01, 2020
WJOG10617G	(Study Protocol) Kenro Hirata et al.Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group. BMC Cancer 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1.
WJOG 9116L/ LOGIK 1603	(Study Protocol) Kazushige Wakuda et al.A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) BMC Cancer. 20(1):370 (2020)
WJOG7312G	Takako Eguchi Nakajima et al.Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer . 2020 Jul;23(4):677-688.
WJOG6510GTR	Hiroya Taniguchi, et al.Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR). Journal of Cancer Science and Clinical Therapeutics 4 (2020): 538-549.
WJOG10517G	(Study Protocol) Toshiki Masuishi, et al.WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases. FUTURE ONCOLOGYVOL. 16, NO. 20

2019年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG6911L	Hiroaki Akamatsu et al.A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations (WJOG6911L). Clinical Lung Cancer, Volume 20, Issue 1, Pages e25-e27, 2019
WJOG8114LTR	Hiroaki Akamatsu et al.Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer 131: 128–133, 2019.
WJOG8715L	Hiroaki Akamatsu et al.Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clinical Lung Cancer, Volume 20, Issue 4, Pages e492–e494, 2019.
WJOG4607L	Kenji Suzuki et al.Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg: J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907.
WJOG4708L	Tatsuo Kimura et al.Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L). Jpn J Clin Oncol, Volume 49, Issue 10, October 2019, Pages 893–894.
WJTOG3405	Hiroshige Yoshioka et al.Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Annals of Oncology 30: 1978–1984, 2019

2018年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG6110B	Toshimi Takano et al.A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes:WJOG6110B/ELTOP. The Breast, Vol. 40, p67–75 (Published online: April 23, 2018)
WJOG5308L	Fumihiro Tanaka et al.Induction Chemo-radiation (50Gy) Followed by Surgery for Stage IIIA-N2 Non-small Cell Lung Cancer. The Annals of Thoracic Surgery, 106(4): 1018–1024, 2018
WJOG5008L	Tomonari Sasaki et al.A randomized phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. British Journal of Cancer, 119: 675-682, 2018

2017年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
PCI	Toshiaki Takahashi et al.Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017. Published Online. March 23, 2017
WJOG7212G	Yuji Miura et al.Five-weekly S-1 plus cisplatin with trastuzumab in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer:Jan;21(1):84-95, 2018
J-SONIC	Kohei Otsubo et al.Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced NoneSmall-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, Vol. -, No. -, — ª 2017 Elsevier Inc. All rights reserved. 2017.06 (Trail in Progress)

2016年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG5910L	Masayuki Takeda et al.Bevacizumab Beyond Disease Progression After First-Line Treatment With Bevacizumab Plus Chemotherapy in Advanced Nonsquamous Non–Small Cell Lung Cancer (West Japan Oncology Group 5910L): An Open-Label, Randomized, Phase2 Trial. Cancer 122(7): 1050–1059, 2016
WJOG5108L	Yoshiko Urata et al.Randomized Phase III Study Comparing Gefitinib with Erlotinib in Patients with Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L Journal of Clinical Oncology 34(27): 3248-3257, 2016
WJOG4407G	Kentaro Yamazaki et al.Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Annals of Oncology 27 (8): 1539-1546, 2016
WJOG6711L	Takekazu Iwata et al.A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respiratory Research 17: 90, 2016
WJOG8014LTR	Takayuki Takahama et al.Detection of the T790M mutation of EGFR in plasma of advanced non 13;small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget 7(36): 58492-58499, 2016
WJOG6210G	Kohei Shitara et al.Randomized study of FOLFIRI plus either panitumumab or evacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci 107: 1843-1850, 2016

2015年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJOG4207L	Fumihiko Hirai et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207 L. Annals of Oncology 26(2): 363-368, 2015.
JCOG0803/ WJOG4307L	Tetsuya Abe et al. Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non?Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L. Journal of Clinical Oncology 33(6): 575-581, 2015.
WJOG4107	Yasuo Iwamoto et al. Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer. Clin Cancer Res 21(23): 5245-5252, 2015.
WJOG5208L	Takehito Shukuya et al. Nedaplatin plus docetaxel versus cipliatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung. Lancet Oncol 16(16): 1630–1638, 2015.

2014年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG0302	Taishi Harada, et al. A phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer. Jpn J Clin Oncol 44(2): 127-133, 2014
WJOG6611LTR	Isamu Okamoto, et al. Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget 5(8): 2293-2304, 2014
WJTOG3806	Haruyasu Murakami, et al. A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non–small-cell Lung Cancer: West Japan Oncology Group. Cancer Science 105(8): 989–995, 2014

2013年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG3405	Hiroaki Akamatsu et al. Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405) Jpn. J. Clin. Oncol.43(6): 664-668, 2013
WJTOG3605	Hiroshige Yoshioka, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Annals of Oncology 24(5): 1326-1331, 2013
WJOG3906L	Yoshihito Kogure, et al. Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung CancerResults of West Japan Oncology Group (WJOG) Study 3906L. Journal of Thoracic Oncology 8(6):753-758, 2013.
WJOG4007	Shuichi Hironaka, et al. Randomized, Open-label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG4007 Trial. Journal of Clinical Oncology 31(35): 4438-4444, 2013

2012年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG0004	Hiroshi Saito et al. Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2. West Japan Thoracic Oncology Group 0004. Am J Clin Oncol 35(1): 58-63, 2012
WJTOG3305	Takuhito Tada et al. A phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer: WJTOG3305 International Journal of Radiation Oncology • Biology • Physics (IJROBP) 83(1): 327-331, 2012
WJTOG2905	Takayasu Kurata et al. A combination phase I /II study of gemcitabine with　carboplatin for previously untreated elderly non-small cell lung cancer; WJTOG 2905. Lung Cancer 77(1): 110-105,2012
WJTOG9903	Nobuyuki Katakami et al. A phase 3 study of induction treatment with concurrent chemorad iotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) Cancer Volume 118( 24): 6126–6135 , 2012
WJOG5910L	Study Protocol Introduction Masayuki Takeda et al. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG5910L) BMC Cancer 12:327-, 2012
WJTOG3005	Hideyuki Harada et al. Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI) . Int J Radiat Oncol Biol Phys. 82(5): 1777-1782, 2012

2011年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG3706	Yukito Ichinose et al. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer. A muti-institutional phase II trial (West Japan Thoracic Oncology Group 3706). Journal of Thoracic Oncology 6(2): 2069-2075, 2011
WJTOG0402	Masashi Kobayashi et al. Phase II Study of Gefitinib as a First-line Therapy in Elderly Patients with Lung Adenocarcinoma: WJTOG 0402. Jpn J Clin Oncol 41(8): 948-952, 2011

2010年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG3405	Tetsuya Mitsudomi et.al. Gefitinib versus cisplatin/docetaxel in patients with non-small cell lung cancer harbouring mutations of epidermal growth factor receptor (WJTOG3405): a randomized phase 3 trial. Lancet Oncol 11(2):121-128, 2010.
WJTOG0401	Hiroyasu Kaneda et al. Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401). Journal of Thoracic Oncology 5(1): 105-109, 2010
WJTOG0301	Masashi Kobayashi et al. Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patientswith Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301. Journal of Thoracic Oncology 5(7): 1075-1080, 2010.
WJTOG0203	Koji Takeda et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol 28(5): 753-760, 2010
WJTOG0105	Nobuyuki Yamamoto et al. Phase III comparative study of a second generation regimen and third generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Oncology Group WJTOG0105. J Clin Oncol 28(23): 3739-3745, 2010
WJTOG3605	Isamu Okamoto et al. Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. J Clin Oncol 28 (36): 5240-5246, 2010

2009年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG0202	Takayasu Kurata et al. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. （WJTOG0202）Journal of Thoracic Oncology 4(5): 644-648, 2009
–	Satoshi Morita et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15 (13): 4493-4498, 2009

2008年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG0403	Kenji Tamura et al. Multicenter prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutation: results of the West Japan Oncology Group trial (WJTOG0403). Br J Cancer 98: 907-914, 2008
WJTOG3505	Isamu Okamoto et al. Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505. Clin Cancer Res 14 (16): 5250-5254, 2008

2007年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG0002	Yasumasa Nishimura et al. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002). Int J Radiat Oncol Biol Phys. 69(3): 786-792, 2007
–	Koji Takeda et. al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group study. Invest New Drugs 25(4): 377-83, 2007

2006年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
–	Masahiko Ando et al. Predictive Factors for Interstitial Lung Disease, Antitumor Response and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib. J Clin Oncol 24(16): 2549-2556, 2006
WJTOG9902	Hiroshi Saito et al. PhaseⅡStudy of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 24(33): 5247-5252, 2006
WJTOG9904	Shinzoh Kudoh et al. Phase Ⅲ Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG9904). J Clin Oncol 24(22): 3657-3663, 2006
WJTOG0104	Nobuyuki Yamamoto et al. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107(3): 599-605, 2006

2005年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
-	Shinzoh Kudoh et al. Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: A phase II trial of West Japan Thoracic Oncology Group. Lung Cancer 49(2): 263-9, 2005

2004年　発表論文一覧

研究No	執筆者/論文タイトル/掲載誌
WJTOG9803	Nobuyuki Yamamoto et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)　Br J Cancer 90(1): 87-92, 2004
WJTOG9908	Nobuyuki Katakami et al. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43(1): 93-100, 2004